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Background: We evaluated the psychometric proprieties of the Screening for Aphasia in NeuroDegeneration 
(SAND) battery in Italian Primary Progressive Aphasia (PPA) and movement disorder (MD) patients. Methods: 
The sample included 30 consecutive PPA and 45 MD patients who completed the SAND battery together with 
a clinical interview and a neurological/neuropsychological examination and 134 healthy subjects (HC). 
Results: The SAND battery showed good internal consistency and good convergent and divergent validity. 
ROC analysis revealed an AUC of 0.978 for PPA vs HC and 0.786 for PPA vs MD. A cut-off of ≥3 gave a 
Sensitivity 0.933 and a Specificity 0.946 for discriminating PPA vs HC; whereas a cut off ≥5 gave a Sensitivity 
of 0.767% and Specificity 0.667 for discriminating PPA vs MD. Conclusions: These results indicate that the 
SAND battery is an adequate, reliable and valid diagnostic tool for PPA. 
 




The language network can be selectively affected by neurodegeneration, leading to progressive language 
dysfunction (primary progressive aphasia, PPA). After the seminal description of slowly progressive aphasia 
by Mesulam [1], many studies have been dedicated to this heterogeneous group of clinical conditions, due to 
different pathologies, in which language impairment is the main sign at onset, and remains the prominent 
clinical feature during many years of progression. The consensus paper  on the definition of PPA and its clinical 
subtypes recognizes three different variants: non-fluent/agrammatic (nf/a-PPA), semantic variant PPA (sv-
PPA) and logopenic PPA (lp-PPA) [2]. Each of these variants presents with a different pattern of speech and 
language deficits and brain imaging features [3].  The diagnosis of PPA is predominantly based on the clinical 
examination, including detailed history from patient and informant, and neurological and neuropsychological 
evaluation. Most language tests in common use, such as the Aachener Aphasie Test (AAT) [4] and the Boston 
Diagnostic Aphasia Examination [5], have been developed for the evaluation of aphasia due to stroke, which, 
besides having a different prognosis, is characterized by language profiles that can be very different from PPA 
[6]. Given the dearth of specific tools aimed at assessing language impairments in neurodegenerative diseases 
[7], we developed a Screening Battery for Aphasia in NeuroDegeneration (SAND) [8],  based on the Mini 
Standard Language Examination proposed by Garrard and Ahmed [9]. The SAND battery aims at the detection 
of language disorders through the assessment of different components of language. It includes nine subtests: 
picture naming, word and sentence comprehension, word and sentence repetition, reading, semantic 
association, writing and picture description. It has been developed on the basis of the recommendations of 
current diagnostic guidelines [2] and of a comprehensive review of the language deficits in PPA subtypes. The 
claim that the SAND battery is adequate to detect language disorders requires the assessment of its construct, 
clinical validity and of its diagnostic accuracy. To this aim, we studied a group of participants with PPA, a group 
of healthy controls (HC) and a group of patients with movement disorders-MD (Parkinson’s disease-PD and 
Progressive Supranuclear Palsy-PSP). We expected the PPA patients to be the most impaired group, as 
aphasia is the major symptom in these patients. Healthy individuals were expected to perform close to ceiling. 
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In the case of MD, PD patients were expected to show normal or mildly affected language performance [10]. 
A similar prediction could be made for PSP patients, since those presenting with a clinical picture of nf/a-PPA 
were excluded. The psychometric properties of the SAND battery and the discriminatory power in detecting 
PPA language dysfunction were assessed by comparing PPA with HC and with MD, estimating the Area Under 
the Curve (AUC), the Sensitivity and the Specificity.   
 
MATERIAL AND METHODS 
Participants  
Two patient samples were included in the study: 
Patients with a clinical diagnosis of PPA according to published guidelines [2], based on audiotapes of 
language and cognitive testing, history, and review of imaging (magnetic resonance imaging or positron 
emission tomography). Those patients not fulfilling the diagnostic criteria for a specific variant were assigned 
the label “unclassifiable”. These patients did not present the typical features of any variant, but only anomia or 
were characterized by features of more than one variant (e.g., non-fluent and logopenic). 
 
Patients with a clinical diagnosis of Parkinson’s disease (PD) or Progressive Supranuclear Palsy (PSP). 
Patients with PD [11], and  with probable or possible PSP [12]  were clinically diagnosed. Motor impairment 
severity was assessed using Unified Parkinson's disease rating scale U-PDRS [13] for PD patients and Natural 
History and Neuroprotection in Parkinson Plus Syndromes-NIPPS-PPS [14] for PSP patients. All patients were 
recruited in a movement disorder unit. Features of language impairment could be present but were not the 
primary cause of referral for any of these patients. The SAND data were collected as part of a comprehensive 
study of cognition in MD. 
Enrollment started in May 2015 and ended in February 2017 Participants were selected among the outpatients 
in hospital located in different Italian areas (Milan, Florence, Bari and Salerno). 
Specifically, criteria for inclusion were: (i) availability of a audiotaped language examinations in order to allow 
an offline analysis of connected speech; (ii) Mini-Mental State Examination-MMSE [15] of at least 10; (iii) Italian 
native speaker; (iv) sufficiently intelligible speech, such that the intended target could be determined for the 
majority of words; (v) intact or corrected auditory and visual functions; (vi) successful completion of the 
experimental task. 
Patients were excluded in the case of: (1) major psychiatric disorders [16]; (2) organic illness affecting the 
brain according to the International Classification Disorder [17]; (3) significant history of head injury; (4) major 
systemic diseases or medical complications, including thyroid disorders and sensory disorders (i.e., blindness 
or deafness); and (5) history of drug or alcohol addiction.  
Informed written consent was obtained from all participants. The local Hospital ethical committee approved the 
study protocol. Information collected during the course of the research was kept confidential, the subjects’ 
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names and details were removed to prevent identification of participants and data storage was password 
protected with data access restricted to study personnel. 
All study participants underwent extensive studies at baseline, following a diagnostic protocol that included 
medical, neurological, neuropsychological and neuroimaging investigations (with magnetic resonance imaging 
or positron emission tomography). Further examinations, such as cerebrospinal fluid markers (β-amyloid and 
tau protein concentration) were obtained for a small group of patients in order to improve the accuracy of the 
diagnosis. Neurologists and neuropsychologists with experience in cognitive disorders and/or movement 
disorders examined all patients. 
A group of HC was enrolled from a convenience sample of volunteers recruited in the centers included in the 
study. The group of HC was the same recruited for the collection of normative data. Subjects who reported a 
history of neurological or psychiatric illnesses or with a corrected score of less than 24 at MMSE were excluded 
[15].  
A total of 92 patients were recruited (43 patients with PPA, 49 patients with MD). We excluded thirteen patients 
with PPA because they were too severely affected to perform a full neuropsychological assessment, 3 patients 
with MD (2 PSP and 1 PD) who fulfilled the criteria for dementia and 1 PSP patient with nf/a-PPA. Therefore, 
the global sample (75 patients, 43 males and 32 females, age range 42–85 years) thus included three different 
diagnostic groups: 30 PPA patients, including 8 sv-PPA, 12 lp-PPA, 6 nf/a-PPA, 4 unclassifiable PPA, and 45 
MD patients, 24 with PD and 21 with PSP. The HC group included 130 native Italian speakers (54 males), 
aged over 45 years – both sexes, with an educational level of >1 year, with a mean age of 63.30 (SD =11.30, 
range 45–85 years) and a mean of 10.5 years of education (SD =4.89; range 2–25). 
Data on demographic and clinical features of all patients and HC included in the study are reported in Table 
1. 
[Insert here Table 1] 
SAND procedure 
All participants were given the SAND battery, whose normative values have already been published [8]. The 
entire battery takes less than 20 minutes to administer and yields scores for each of the nine subtests. Picture 
description and written description analysis yields additional subscores, resulting in a total of twenty-three task-
related scores (see Supplementary Materials Figure 1S). 
 
Cognitive assessment  
In addition to the SAND battery, PPA patients were administered an extensive battery of standardised 
neuropsychological tests in a 2-hr session. The tests covered the following cognitive domains: attention, 
executive functions, memory, language, and visuospatial processing (see Supplementary Materials). For each 
test score, we report the corresponding adjusted score obtained on the basis of the normative data (i.e., 




Demographics and clinical variables 
Quantitative variables are reported as mean, standard deviation, median and range, while qualitative variables 
are reported as frequencies and percentages. Comparisons among the diagnostic groups for demographic 
and clinical variables was made using Kruskal Wallis test by ranks and Nemenyi post-hoc tests for quantitative 
variables, or Pearson’s chi-squared test for qualitative variables. The disease duration of the two patient groups 
(PPA and MD) was compared using the Mann-Whitney U Test. 
 
Global diagnostic score 
Before proceeding with statistical analysis, a Global Score of the SAND battery was calculated. The Global 
Score includes the twenty-three task-related-scores. Three steps were followed: 
1) the raw scores were adjusted by adding or subtracting the influence of age, sex and education and 
corrected using normative data; 
2) corrected scores were compared with the corresponding cut-off values obtained from HC; 
3) the sum of the twenty-three dichotomous variables (1=pathological 0=normal) represents the global score, 
with higher scores indicating a more severe impairment (range 0-23). 
Reliability and Construct validity 
The reliability of the Internal Consistency of the SAND battery was estimated using Cronbach’s alpha 
coefficient [18]. Construct validity was assessed considering only PPA patients and using corrected scores of 
the task-related-scores. In order to assess construct validity, a correlation analysis between corrected task-
related-scores and the other language/non-language tests was carried out. Tables 2 and 3 display the 
correlations results. All the correlations were estimated using the Spearman’s rank correlation coefficient, in 
order to deal with the non-normal distributions of the scores. 
 
ROC analyses  
The ROC curve for SAND Global Score was used to detect the optimal cut-off score maximizing both sensitivity 
and specificity. The AUC, sensitivity and specificity were calculated along with their 95% bootstrapped 
confidence interval (CI), considering 2000 sampling replications. Positive predictive value (PPV) and Negative 
predictive value (NPV) were also reported for the optimal cut-off. The ROC analysis, to assess the 
discriminatory power of the SAND battery (global score), was used for both comparisons: PPA vs HC and PPA 
vs MD.  All analyses were performed using R (v 3.3.1) and Rstudio (v 1.0.153). A p value lower than .05 was 




No significant differences were detected between groups in demographic data, with the exception of age, 
where HC were younger than the PPA group (p <0.001); however, this variable does not influence the results, 
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since all performances have been adjusted for age, sex and education effects.  MD patients had a significant 
longer disease duration than PPA patients (p=0.007).  
Global diagnostic score 
Global scores of the SAND battery for HC vs PPA vs MD are displayed in Supplementary Materials Figure 2S. 
As expected, PPA patients performed worse than HC (p <0.001) and MD (p=0.011). HC performances were 
close to ceiling. A significantly worse performance was observed in MD patients compared to HC (p<0.001).  
 
 
Reliability and Construct Validity 
The Cronbach’s alpha coefficient of the global score of the SAND battery was 0.864 as computed from the 
whole sample.Table 2 shows the correlation analysis among the sub-scores of the SAND battery and the 
language tests. All SAND sub-scores were correlated with the conventional language test (all p<0.005). The 
strongest correlations were found for sentence repetition with the ENPA sentence repetition task (r=0.85) and 
for the naming subtest with the CAGI naming task (r=0.82). Table 3 shows the correlations between the global 
score of the SAND battery and non-language tests, which were not significant, with the exception of tasks with 
a relevant linguistic component (MMSE, digit span).  
 
[Insert here Table 2 and Table 3] 
 
ROC analyses 
The ROC curve showed that the optimal cut-off score for the comparison of the PPA sample vs HC was 3, 
achieving a high sensitivity of 0.933 (95% CI 0.833 to 1.000), a high specificity of 0.946 (95% CI 0.908 to 
0.985), a positive predictive value (PPV) of 0.800 and a negative predictive value (NPV) of 0.984 (Figure 1a). 
The overall discriminatory power (AUC) for the SAND battery was 0.978 (95% CI 0.945 to 0.999). ROC 
analyses are shown in Figure 1b. A score of 2 classified PPA vs HC with 0.933 sensitivity (95% CI 0.833 to 
1.000) and 0.854 specificity (95% CI 0.792 to 0.908). A score of 4 had a sensitivity of 0.833 (95% CI 0.700 to 
0.967) and a specificity of 1.000 (95% CI 1.000 to 1.000). 
For the comparison between PPA and MD (PD + PSP) patients, the ROC curve showed that the optimal cut-
off was 5, achieving a high sensitivity of 0.767 (95% CI 0.600 to 0.900), and a specificity of 0.667 (95% CI 
0.533 to 0.800), a PPV of 0.605 and a NPV of 0.811 (Figure 1c). The overall discriminatory power (AUC) was 
0.786 (95% CI 0.670 to 0.882). ROC analyses are shown in Figure 1d. A score of 6 accurately classified PPA 
vs MD with 0.667 sensitivity (95% CI 0.500 to 0.883) and 0.689 specificity (95% CI 0.555 to 0.822). A score of 
4 had a sensitivity of 0.833 (95% CI 0.667 to 0.967) and specificity of 0.578 (95% CI 0.444 to 0.711). 




Language assessment has a critical role in the clinical diagnosis of neurodegenerative diseases, in particular 
in the case of PPA. However, only a few attempts have been made to develop specific tools to diagnose, 
clinically classify and follow up the heterogeneous group of PPA patients. Recently, a systematic review 
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identified the few neuropsychological tests available for the assessment of speech and language disorders in 
PPA and discussed their limitations [7]. This is the main reason leading to the development of the SAND 
battery [8]. In this study, we explored its clinical validity and psychometric characteristics. Our findings suggest 
that the SAND battery provides useful information in the clinical diagnosis of PPA patients. 
 
Consistency and validity. The good internal consistency, with a Cronbach coefficient of .864 for the global 
score, means that the SAND scores are consistent with each other for the content that they measure. The data 
about construct validity showed that the SAND is a valid measure of language functions. Specifically, the 
strength of the correlation among the nine scores of the battery and the other measures assessing comparable 
components of language performance (i.e., naming, comprehension etc.) was high, compatible with a shared 
general language function dimension. Divergent validity was also assessed, analyzing the correlation between 
SAND global score and non-language tasks. Two measures were significantly associated with the global score: 
1) the MMSE, which includes language subtests (e.g., naming, writing and repetition of sentence); 2) the Digit 
Span backwards, which can be expected to correlate with the two tasks with a relevant working memory load 
e.g., repetition of single word/non-word and of sentences. 
Clinical usefulness. As a screening battery, the main goal of the SAND is to determine whether an individual 
has language impairment. Our results clearly indicate that an impaired performance on the test can be used 
to identify individuals with clinically significant language impairments.  The diagnostic accuracy for specific 
conditions needs to be confirmed using a reliable gold standard, i.e. neuropathological confirmation, positivity 
of reliable biomarkers [19], or presence of pathogenetic  mutations [20], associated with FTD or with 
Alzheimer’s Disease (AD) [21]. A diagnosis by independent experts using the current criteria [2] is at the 
moment the only available option in the case of PPA patients.  
Speech and language disorders may occur in corticobasal degeneration and PSP. Patients with these 
diagnoses can actually fulfill the criteria for nf/a-PPA and Apraxia of Speech [22], [23], and were excluded from 
the present MD sample. The SAND battery is thus also able to discriminate non-aphasic MD patients from 
controls, providing a good evidence for its sensitivity in detecting subtle language deficits in neurodegenerative 
diseases in general. 
The SAND battery represents a first step towards a concise multilingual standard language examination, as a 
fast and simple tool to help clinicians and researchers in the clinical diagnosis of PPA. A further development 
of this battery will lead to identify the combinations of tests and test items that most reliably and accurately 
classify patients based on neuropsychological/linguistic features. The use of machine learning algorithms, as 
reported by other several studies, may represent a useful approach to this aim (e.g., [24- 26]), when a 
sufficiently large dataset allowing the identification of which test/test item leads to the best discrimination of 
deficits in each variant will become available. 
 
Limitations. A limitation is that the global score may be biased by the use of cut-off values obtained from the 
same control group used in the validation process. The group of MD patients was included in order to compare 
the performance of a different clinical population. Another limitation is the small sample size. Therefore, our 
findings require replication in larger populations to properly assess generalization. A minor point concerns PSP 
8 
 
patients, which were included in the MD group even if they may clinically present as the non-fluent/agrammatic 
variant PPA [27]. The present sample, however, was recruited from MD clinics, and we excluded cases fulfilling 
the criteria for PPA. 
CONCLUSION 
Taken together, our findings encourage the use in clinical practice of the SAND battery, which has been shown 
to be able to identify patients with PPA. Overall, the SAND showed good validity as a screening instrument to 
detect language impairment in patients with neurodegenerative disorders. The satisfactory PPVs and NPVs 
and the limited length of this cognitive and language measure makes this battery especially useful in clinical 
contexts [28]. Cognitive and language tools are inexpensive and low-tech additions to the diagnostic process 
that can be used in a variety of clinical settings: primary, secondary or tertiary care and research studies. The 
SAND battery may be especially useful in settings where a complete neuropsychological/language 
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Figure captions 
Fig. 1a) Summary of the diagnostic accuracy of the SAND battery for the comparison PPA vs HC. 1b) ROC 
curve for the global score of the SAND battery to detect patients with language dysfunction evaluated in the 
sample of PPA vs HC (SEN, Sensitivity, SPE, Specificity, AUC, Area Under the receiver operating 
characteristic Curve; ROC, receiver-operating characteristic). 1c) Summary of the diagnostic accuracy of the 
SAND battery for the comparison MD vs. PPA. 1d) ROC curve for the global score of SAND battery to detect 
patients with language dysfunction evaluated in the comparison PPA vs MD. 
 
 
Table 1 Demographic characteristics and clinical data of enrolled subjects. HC=Healthy Controls; 
PPA=Primary Progressive Aphasia; MD= movement disorders; PD=Parkinson’s Disease; PSP=Progressive 
Supranuclear Palsy. The p-value for the overall differences test (p) and p-values for the post-hoc analysis 
(pairwise comparisons: PPA vs HC; MD vs HC and PPA vs MD) are reported. 
Variables HC PPA MD  
(PD + PSP) 






Sample size 130 30 45 (24+21) - - - - 








<0.001 <0.001 0.127 0.196 








0.700 - - - 
Sex (%m) 41.54% 53.33% 60.00% 0.078 - - - 
Disease duration in 
months mean  
(± st.dev.) 




0.007 - - - 








<0.001 <0.001 <0.001 0.022 








<0.001 <0.001 <0.001 0.011 
UPDRS for PD - - 15.80 (±7.97) -    
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Table 2 Correlation analysis among the sub-scores of the SAND battery and the state-of art language tests. 
Note. AAT= Aachener Aphasie Test, ENPA= Esame Neuropsicologico dell’Afasia, PPT= Pyramids and Palm 
Tree Test. Negative values refer to those tests for which the higher the score the worse the performance. 
*|0.30| < r < |0.50| moderate correlation; **r > |0.50| strong correlation. The following correlations were 
performed: Naming with CAGI naming; Auditory Sentence Comprehension with ENPA Auditory Sentence 
Comprehension; Word Comprehension with CAGI word-picture matching; Word/non-word repetition with 
ENPA Word/non-word repetition; Sentence Repetition with AAT Sentence Repetition, AAT Total score 
repetition and ENPA Sentence repetition; Reading with TIB total errors score, Writing – syntactic 
structure/Sentences with ENPA Sentence writing; Semantic Association with PPT total score; Picture 
description – nouns/words with Category Fluency and CAGI naming.  
 
Tasks SAND Language Tests Spearman P-value Sample 
size 
Naming CAGI naming 0.82 <0.001 28 
Sentence Comprehension 
Token Test 0.63 <0.001 24 
Auditory sentence comprehension 
(ENPA) 
0.45 0.007 17 
Word Comprehension CAGI word-picture matching 0.67 <0.001 25 
Word/non-word repetition Word/ non-word repetition (ENPA) 0.54 0.009 22 
Sentence Repetition 
Sentence repetition (AAT) 0.74 0.002 14 
Total score repetition (AAT) 0.84 <0.001 16 
Sentence repetition (ENPA) 0.85 <0.001 22 
Reading TIB -0.59 0.012 17 
Writing – syntactic 
structure/Sentences 
Sentence writing (ENPA) 0.49 0.020 22 
Semantic Association PPT 0.50 0.040 17 
Picture description – 
nouns/words 
Category Fluency 0.55 0.003 26 











Table 3 Correlation analysis among the sub-scores of SAND battery and the non-language tests. Note. RAVLT 
= Rey Auditory Verbal Learning Test; RCF = Rey Complex Figure; SCWT = Stroop Colour-Word Test, TMT-
AB = Trail Making Test part A and B; FAB = Frontal Assessment Battery; CDT = Clock Drawing Test. Negative 
values refer to those tests for which the higher the score the worse the performance. *|.30| < r < |.50| moderate 
correlation; **r > |.50| strong correlation. The Global Score of the SAND battery was correlated with the 
following tests: MMSE, RAVLT (immediate, delayed recall, recognition and false alarms), Digit Span (backward 
and forward), Corsi Span backward, RCF (copy and delayed recall), SCWT time and errors), TMT-AB, FAB 
and CDT. 
Global Score  
SAND battery 
Non Language Tests Spearman P-value Sample size  
MMSE -0.56 0.001 29 
RAVLT immediate -0.44 0.059 19 
RAVLT recall -0.24 0.319 19 
RAVL recognition -0.51 0.073 13 
RAVLT false allarms  0.34 0.304 11 
Digit Span backward -0.40 0.034 28 
Digit Span forward -0.29 0.144 27 
Corsi Span backward -0.19 0.341 27 
RCF Copy -0.12 0.578 25 
RCF Recall  -0.36 0.084 24 
SCWT time 0.30 0.323 13 
SCWT errors 0.34 0.251 13 
TMT-A 0.34 0.108 23 
TMT-B 0.49 0.060 15 
TMT-AB 0.47 0.076 15 
FAB -0.33 0.132 22 
CDT -0.13 0.585 19 
 
